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ABSTRACT 
 
Though recognized previously as “shell shock” or “combat neurosis” Post-
traumatic Stress Disorder (PTSD) is an anxiety disorder that was first introduced 
in the third edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-III) in 1980.  Diagnosis of PTSD requires the experience of a traumatic 
event followed by symptoms including avoidance, hyperarousal, re-experiencing, 
numbing and intense fear.  The current treatment options include psychotherapy 
and pharmacotherapy.  Brain stimulation is also emerging as an effective 
treatment option.  The most widely studied and successful treatment is termed 
Prolonged Exposure therapy (PE).  This involves the therapeutic repetition of the 
traumatic experience in order for the patient to understand that they are no 
longer in danger.  Despite the effectiveness of PE, many individuals continue to 
suffer from PTSD.  There are several obstacles between research and practice, 
as well as barriers to care for those suffering from PTSD.  Even when evidence 
based practice is applied to those in need, there is still a high rate of treatment 
failures.  Further research must be done to determine the best course of 
treatment for the increasing number of individuals suffering from PTSD. 
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INTRODUCTION 
 
The term Post-traumatic Stress Disorder (PTSD) was only first introduced 
in the third edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-III) in 1980.  Despite its relatively recent introduction, the symptoms have 
long been recognized by other names such as ‘shell shock’ or ‘combat neurosis.’  
Since the inception of the term PTSD, research has increased rapidly to attempt 
to treat this complex disorder.   
PTSD is an anxiety disorder that affects individuals who have directly 
experienced a traumatic event.  The traumatic event may involve “actual or 
threatened death or serious injury, or other threat to one's physical integrity; or 
witnessing an event that involves death, injury, or a threat to the physical integrity 
of another person; or learning about unexpected or violent death, serious harm, 
or threat of death or injury experienced by a family member or other close 
associate” (DSM-IV-TR, 2000).  Traumatic events can include violent physical 
assault, natural disasters, rape, and automobile accidents.  One of the most 
common forms of trauma experienced by individuals with PTSD is combat.  This 
is becoming an increasingly common occurrence, as the United States has been 
at war in Iraq and Afghanistan for over ten years.  These wars have included 
Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF) and 
Operation New Dawn (OND).  During these operations over two million American 
service members have been deployed, and nearly half of them more than once 
(Wall, 2012).  Due to advancements in protective equipment and battlefield 
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medicine, the survival rate of injury is currently nine in ten for OEF and OIF (Wall, 
2012). 
In addition to the experience of a traumatic event, a PTSD diagnosis 
requires the individual to respond with an intense fear and/or helplessness, with 
characteristic symptoms including persistent reexperiencing of the traumatic 
events, avoidance of stimuli associated with the trauma, numbing of general 
responsiveness, and symptoms of increased arousal.  When all of these 
symptoms are present for at least one month, causing significant distress and 
functional impairment, the disorder can be diagnosed as PTSD (DSM-IV-TR, 
2000). 
The three main symptoms of PTSD are broadly classified as re-
experiencing, avoidance, and increased arousal.  Each of these classes of 
symptoms may present in varying ways.  Reexperiencing of the traumatic event 
may occur by intrusive thoughts and images, recurrent dreams of the event, 
acting as if the event were recurring, psychological distress when exposed to 
external or internal cues that remind the individual of the traumatic event or 
physiological reactivity to these external or internal cues.  Avoidance may 
present as an effort to avoid thoughts, feelings, or conversations associated with 
the trauma; efforts to avoid activities, places or people that stimulate recollections 
of the trauma; inability to recall important aspects of the trauma, diminished 
participation or interest in activities; feelings of estrangement or detachment from 
others; restricted range of affect; or sense of a foreshortened future.  Increased 
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arousal may be indicated by difficulty sleeping, irritability, outbursts of anger, 
difficulty with concentration, hypervigilance, and exaggerated startle response 
(DSM-IV-TR, 2000). 
PTSD is a complex and heterogeneous disorder, affecting many different 
types of people in many different ways.  It also has acute, chronic and delayed 
onset forms.  If symptoms persist for longer than three months, the individual is 
considered to have chronic PTSD.  If symptoms last for less than three months, 
but at least one month it is considered acute PTSD.  Prior to one month, PTSD 
cannot be diagnosed, but the symptoms are instead considered an acute stress 
reaction or acute stress disorder.  When the onset of symptoms is at least six 
months following the traumatic event, the individual is considered to have 
delayed onset PTSD (DSM-IV-TR, 2000). 
 
Figure 1. Stress Reaction Timeline (“VA/DoD Clinical Practice Guidelines,” 2009) 
 
The current treatment options for PTSD have a high rate of failure (Cukor 
et al., 2009).  As many as 41% of patients with PTSD fail to respond to 
pharmacotherapy (Novakovic et al., 2011) so it is imperative that alternative 
treatment options be identified. 
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This review will focus on, but not be completely limited to, PTSD in military 
populations, including both veterans as well as active duty service members.  It 
has been shown that veterans with PTSD have more severe symptoms than 
civilians with PTSD.  Combat exposure specifically results in worse 
symptomology than other types of trauma.  (Carter, Capone, & Short, 2011). 
Combat exposures, specifically those involving witness of death, threat of death 
and witnessing or experiencing serious injury, have been shown to be a 
significant risk factor for PTSD among male Marines (Phillips et al., 2010).  
Individuals who experience physical injury as a part of their traumatic experience 
represent a complication to combat exposure as a risk factor.  The patient’s 
physical injury, especially if permanent, serves as a powerful and persistent 
reminder of the trauma (Jeffreys, Capehart, & Friedman, 2012). Ninety-four 
percent of veterans returning from Afghanistan and Iraq have reported 
experiencing such life-threatening, combat-related events (Carter et al., 2011; 
Hoge et al., 2004) putting them directly at risk for developing PTSD. 
While combat exposure is the most stand-out risk factor for development 
of PTSD in military populations, there are other risk factors as well.  In a study of 
deployed male US Marines, past exposures to violence prior to entering the 
Marine Corps were also shown to put individuals at greater risk of developing 
PTSD (Phillips et al., 2010). 
Not all individuals exposed to a traumatic event are bound to develop 
PTSD.  A number of genetic and environmental factors prior to the event may 
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play a role in the development of the disorder.  Some individuals may be pre-
disposed to developing PTSD.  It is hypothesized that vulnerability stems from 
biological diathesis, early childhood experiences & trauma severity (Novakovic et 
al., 2011).  Additional identified factors include a genetic predisposition, sex, 
social support structures, peritraumatic dissociation and trauma frequency 
(Brewin & Andrews, 2000; Brewin & Holmes, 2003; Jeffreys et al., 2012; Keane, 
Marshall, & Taft, 2006). 
In 1995 it was estimated that the lifetime prevalence of PTSD in the 
general population was 7.8 percent (Kessler, 1995).  It is difficult to estimate the 
actual prevalence of PTSD, especially in military populations.  In Vietnam 
veterans, the lifetime prevalence of PTSD has been estimated to be 18.7 
percent.  The prevalence of PTSD in Veterans of the Iraq and Afghanistan wars 
(OEF/OIF/OND) is estimated to be between 15 and 17 percent.  Many experts 
believe these rates underestimate the actual prevalence of PTSD due to a variety 
of factors (Jeffreys et al., 2012).  One major factor is underreporting, which in 
itself has a variety of causes.  Among active duty personnel there is a stigma 
associated with mental health disorders and fear of negative effect on one’s 
career (Hoge et al., 2004; Iversen et al., 2011; Wall, 2012). 
Not only is PTSD difficult to treat in the short term, but many patients with 
PTSD suffer for a long time.  One case study described a Vietnam veteran who 
suffered from re-experiencing, avoidance, and hyperarousal symptoms for more 
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than 40 years following several traumatic events during his deployment in 
Vietnam.  (Carter et al., 2011) 
Treatment options include preventative measures, immediately following a 
traumatic event (Roberts et al., 2010). as well as treatments that begin following 
a diagnosis of PTSD.  The two major types of treatment include psychological 
interventions and pharmaceutical interventions (Hetrick et al., 2010).  Brain 
stimulation modalities are also emerging as effective treatments for PTSD. 
Psychological interventions include Cognitive Behavioral Therapy (CBT), 
eye movement desensitization and reprocessing (EMDR) supportive counseling, 
interpersonal therapy and psychodynamic treatments (Hetrick et al., 2010).   
Pharmaceutical interventions commonly include Selective Serotonin 
Reuptake Inhibitors (SSRIs) as well as Selective Norepinephrine Reuptake 
Inhibitors (SNRIs).  There are also a number of emerging pharmaceutical agents 
that hold potential in the treatment of PTSD.   
No brain stimulation modalities are currently FDA approved for the 
treatment of PTSD, but Electroconvulsive Therapy (ECT) and Transcranial 
Magnetic Stimulation (TMS) are commonly used to treat severe depression and 
may also be effective for PTSD.  Other modalities are still under investigation. 
A complicating factor in the treatment of PTSD is that a majority of 
patients have comorbidities such as Traumatic Brain Injury (TBI) or substance 
abuse/dependence.  These comorbidities are limiting for research and in clinical 
practice. 
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Figure 2. 
 Overview of Treatments for PTSD  (“VA/DoD Clinical Practice Guidelines,”2009) 
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PRESENTATION OF PUBLISHED DATA 
 
Psychological Interventions 
 
Cognitive Behavioral Therapy (CBT) is a broad category of 
psychotherapy that encompasses many of the techniques used to treat PTSD.   : 
CBT aims to provide patients with skills to control fear and reduce anxiety and 
promote habituation.  In the case of PTSD treatment, CBT will activate fear by 
(Solomon, 1992). 
 Under the umbrella of cognitive-behavioral therapies are exposure based 
therapies.  These therapies involve the confrontation of fear by patients.  By 
exposing patients to objectively harmless, but feared stimuli, anxiety related to 
these stimuli may be reduced.  The temporal length of the exposures can vary, 
as can the arousal level.  There are also various mediums of exposure including 
imaginal and in vivo.  Specific types of exposure therapy include systematic 
desensitization (SD), and prolonged exposure (PE) therapy (Foa & Meadows, 
1997). 
 
Prolonged Exposure (PE) therapy is currently considered the first line 
treatment for PTSD.  Among cognitive behavioral therapies for treatment of 
PTSD, PE has been the subject of the most extensive study.  Prolonged 
exposure therapy has the greatest number of replications conducted around the 
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world.  It also has the greatest number of comparisons to other evidence-based 
treatments for trauma.  The therapy has been successfully applied to clinical 
practice, is tolerated well by patients, and has shown treatment gains that are 
maintained (Nacasch et al., 2011).  
 
 
 
Figure 3. Plot of Pretreatment and Posttreatment PSS-I Scores in Prolonged 
Exposure Group Versus Treatment as Usual Group.  PSS-I = Posttraumatic 
Stress Disorder Symptoms Scale-Interview Version (Nacasch 2011) 
 
Prolonged exposure therapy was developed by Edna Foa in 1994 to 
include four main components: education-rationale, breathing retraining, 
behavioral (in vivo) exposures, and imaginal exposures.  These four components 
10 
 
are introduced in that specific order over the course of nine treatments sessions.  
The imaginal exposure sessions are recorded, and clients are instructed to listen 
to the recording each day.  They are also instructed engage in behavioral 
exposures of increasing difficulty on a daily basis.  (Resick et al., 2002) 
By systematically exposing patients to memories of traumatic events, they 
can be desensitized and recognize that they are no longer in danger.  The 
theoretical basis of exposure therapy lies in a model of PTSD as a failure to 
extinguish the fear response.  (Foa & Meadows, 1997b; Osuch et al., 2009).  
This model of PTSD is built upon theories such as Lang’s (1979) bioinformation 
theory which views fear as a cognitive structure including representations, 
responses and meaning of specific stimuli.  Using this definition of fear combined 
with Rescorla’s (1988) theory of condition as a change in meaning, PE can be 
viewed as a mechanism by which erroneous associations  are corrected.  By 
activating fear and presenting corrective information this deconditioning can be 
achieved (Foa & Meadows, 1997).  Through this deconditioning, patients are 
able to come to the realizations that “(a) being in objectively safe situations that 
remind one of the trauma is not dangerous; (b) remembering the trauma is not 
equivalent to experiencing it again; (c) anxiety does not remain indefinitely in the 
presence of feared situations or memories, but rather it decreases even without 
avoidance or escape; and (d) experiencing anxiety/PTSD symptoms does not 
lead to loss of control” (Foa & Meadows, 1997). 
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Prolonged Exposure therapy has improved PTSD symptoms in several 
studies over the past decade.  Nacasch (2011) showed that PE is beneficial in 
the amelioration of combat- and terror-related PTSD symptoms.  It was superior 
to treatment as usual in both the short- and long-term reduction of PTSD and 
depression symptoms (Nacasch et al., 2011). 
 
  Systematic Desensitization (SD) is another type of exposure therapy.  
SD uses minimally arousing, imaginal, brief exposures.  Pioneered by Wolpe in 
1958, this technique combines imaginal exposure to feared stimuli with relaxation 
in a graded hierarchical fashion (Foa & Meadows, 1997a).  Though some studies 
have shown improvement in post-trauma symptoms, they generally lacked the 
quality and rigor necessary to draw meaningful conclusions (Foa & Meadows, 
1997a). 
 
In the past, other types of exposure therapies were called imaginal 
flooding and implosive therapy.  These therapies did have some success, but 
have not been studied as extensively as prolonged exposure therapy (Foa & 
Meadows, 1997). 
CBT has been successful, not only in treating PTSD, but in preventing 
PTSD immediately following an acute traumatic event.  Prior to a diagnosis of 
PTSD, an individual may be diagnosed with Acute Stress Disorder (ASD) 
following a traumatic event.  This disorder has some similar features to PTSD, 
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but is specific for symptoms that occur within the first month of trauma (DSM-IV-
TR, 2000). In a randomized controlled trial of 24 individuals with acute stress 
disorder, it was found that only 8% of people fulfilled the diagnostic criteria for 
PTSD following 5 sessions of CBT.  This was compared to 83% of patients who 
fulfilled the diagnostic criteria following 5 sessions of supportive counseling.  
Additionally, of the patients who received CBT, only 17% fulfilled the diagnostic 
criteria for PTSD 6 months later.  This was compared to 67% of the patients who 
received the supportive counseling, 6 months later (Bryant, 1998). 
 
Cognitive Processing Therapy (CPT) is a treatment specifically 
designed for treatment of PTSD resulting from sexual assault.  The therapy 
consists of an exposure component as well as a cognitive therapy component.  
The exposure component consists of writing and reading about the traumatic 
event.  Case studies and a group therapy format have shown this therapy to be 
effective in treating PTSD (Resick & Schnicke, 1992; Resick et al., 2002). While 
Prolonged Exposure therapy is useful to extinguish fear, it is hypothesized that 
CPT may be more effective for patients coping with guilt.  Cognitive therapies 
may help redirect pathological guilt, whereas the types of therapeutic procedures 
used in PE may even be harmful for guilt.  (Resick et al., 2002).  The 
effectiveness of PE on guilt may depend on the type of guilt that a client is 
experiencing.  Global guilt may be more easily dispelled with exposure therapy, 
however PTSD patients are often suffering from guilt cognitions relating to 
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hindsight bias or lack of justification.  They often focus on behaviors during the 
trauma and whether or not the traumatic event may have been preventable.  CPT 
may be effective in treating these specific types of guilt.  (Resick et al., 2002). 
According to the manual of CPT written by Resick and Schnicke (1993), 
Cognitive Processing Therapy begins with the writing of an “impact statement” in 
the first session.  The second session teaches clients to identify and relate 
thoughts and emotions among events.  In the third session, clients are assigned 
to write a detailed account of the trauma for homework and read it back to 
themselves.  In the fourth session, the clients read the account to the therapist.  
In the fifth session, the account is rewritten with the focus of teaching clients to 
challenge their beliefs on the meaning of the traumatic event.  By challenging 
beliefs, clients are able to identify problematic patterns of cognition.  From 
sessions 7-12 clients focus on one theme each week to correct any 
overgeneralized beliefs related to that theme.  In session 11 clients rewrite their 
impact statements to reflect their current beliefs.  The final statements are used 
in the last session to evaluate gains and identify areas that they may wish to 
continue working on.  (Resick et al., 2002).  In a study comparing CPT and PE in 
rape victims, it was found that both therapies were highly successful in treating 
PTSD, including depressive symptoms.  CPT was superior to PE in terms of 
remediating guilt cognitions, as was previously hypothesized.  Both therapies 
showed equal effectiveness for both recent and chronic PTSD and depression.  It 
seems that the number of years that pass following a traumatic event may not 
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actually change the final outcome.  One potential reason for this is that 
individuals with PTSD tend to avoid reminders of the trauma.  This can cause the 
traumatic memory to become more or less static in individuals with chronic PTSD 
(Resick et al., 2002).  The findings of this study are strong, as the methods were 
rigorous and sample size was relatively large (n=121 completed treatment). 
 
Another type of CBT is couples therapy.  There is a clear relationship 
associating PTSD with relationship distress and aggression (Monson, 2012; Taft 
et al., 2011).  PTSD can also cause psychological distress in the other partner, 
and negative interpersonal relationships predict worse treatment outcomes 
(Caska & Renshaw, 2011; Tarrier, Sommerfield, & Pilgrim, 1999).  Previously, 
uncontrolled trials had shown that couples therapy could improve PTSD 
symptoms and relationship satisfaction (Monson, 2004; Monson et al., 2011; 
Monson, 2012; Sautter et al., 2009).  Monson et al. conducted the first 
randomized controlled trial of Cognitive-Behavioral Conjoint Therapy (CBCT) for 
treatment of PTSD, in which cognitive-behavioral approaches were applied to 
couples in which one partner had PTSD (Monson CM, 2012).  A waiting list for 
treatment was used as the control condition in this study.  Compared to the 
waitlist condition, those who received the couples therapy had significant 
improvements in intimate relationship satisfaction, as well as clinically meaningful 
reductions in PTSD symptom severity.  These effects were maintained at three 
month follow-up.  Najavits noted that this study had strengths in including 
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couples of various sexual orientations, detailed descriptions of treatment, use of 
validated assessments, blinded evaluation and fidelity monitoring (Najavits, 
2012).  Najavits criticized Monson’s study for leaving out follow-up data on 
subjects who were on the waiting list as well as those who dropped out of the 
study.  Najavits also criticized the appearance of the sample group as one that 
was “easy to treat,” excluding subjects with severe comorbidities or non-
supportive partners.  The sample size lacked diversity of race and employment 
status as well.  These flaws pointed out by Najavits make it difficult to apply the 
results to the general population.(Najavits, 2012) 
 
Group therapy is another subset of CBT.  Friendships with people in similar 
situations can help individuals to feel safer and more open about their symptoms.  
One case study described a veteran who had confined himself to “his bunker” 
(basement) for decades, but upon commencing group therapy he formed 
friendships with other combat veterans, stating that, “They know exactly how I 
feel.” (Carter et al., 2011) 
 
Hypnotherapy is a psychosocial treatment that has been used for many 
years in the treatment of distress related to trauma.  Several case studies have 
reported hypnosis as being a useful treatment for PTSD, however they lack the 
methodological rigor necessary to apply these results to practice (Foa & 
Meadows, 1997a).   
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Eye Movement Desensitization and Reprocessing (EMDR) is one of the 
newer cognitive behavioral therapies.  It is a form of exposure therapy which is 
accompanied by saccadic eye movements.  While the patient focuses on a 
disturbing image or memory, the patient tracks the therapist’s finger as they wave 
it across the patient’s visual field (Foa & Meadows, 1997a). EDMR has been 
shown to be equally as effective as PE in terms of reducing anger and guilt 
(Stapleton, Taylor, & Asmundson, 2006). 
 
Stress Inoculation Training (SIT) is an anxiety management program.  
The goal of anxiety management programs is to provide ways to manage anxiety 
when it occurs, as opposed to cognitive therapies which aim to correct the 
mechanisms that underlie pathological anxiety (Foa & Meadows, 1997a).  The 
treatment protocol for SIT provides patients with coping skills such as education, 
relaxation, cognitive restructuring and behavioral rehearsal.  (Resick et al., 2002)   
The first controlled trial of SIT was conducted by Resick et al. (1988) and showed 
improvement in fear and anxiety (Resick et al., 1988).  Edna Foa compared SIT 
to PE and found SIT was a viable treatment for PTSD.  However, since both trials 
came from the same research group and only studied female assault victims, 
further research is needed to apply  the results to the general population (Foa,et 
al., 1991; Foa & Meadows, 1997b). 
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Pharmaceutical Interventions 
Although evidence-based psychotherapy focusing on the traumatic event 
(such as PE) is considered the favored treatment for PTSD, pharmacotherapy is 
also an essential treatment option.  Pharmacotherapy may be used in 
conjunction with psychotherapy, or when psychotherapy fails to be successful in 
an individual.  The theory supporting pharmaceutical treatment of PTSD is that 
trauma is a psychobiological event, which can cause long-term neurobiological 
changes in the brain (Solomon, 1992). Several studies aim to determine what 
these changes are in order to best treat them with medication.  Understanding 
the chemical changes that occur in the brain can help to develop 
pharmacological treatments.  There is a considerable amount of research 
devoted to the study of these neurobiological changes in the brain that occur with 
PTSD.  It has been shown that individuals with PTSD have disturbances in the 
neurological integration of the fear circuitry, which is important in the “fight or 
flight” response (Jeffreys et al., 2012; Shin & Handwerger, 2009). Studies have 
also shown that the hypothalamic-pituitary-adrenal regulation is disrupted (De 
Kloet et al., 2006; Jeffreys et al., 2012; Wessa et al., 2006; Yehuda, 2001). There 
is also evidence that key areas such as the amygdala have reduced 
serotoninergic modulation of the fear response (Jeffreys et al., 2012; Murrough et 
al., 2011).  In addition to these lasting changes in the brain, there is research that 
focuses on the changes that occur in the brain in the immediate aftermath of 
trauma.  For example, it has been shown that prolonged adrenergic immediately 
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following trauma has been linked to increased risk for PTSD (Cukor et al., 2009; 
Vaiva, 2003).  
Potential pharmacological interventions include tricyclic antidepressants 
(TCAs), mono-amine oxidase inhibitors (MAOIs), selective serotonin reuptake 
inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), 
anxiolytic medications, mood stabilizers, and antipsychotics (Hetrick et al., 2010). 
The most common pharmacological intervention is SSRIs.  Pharmacological 
interventions may also be combined with psychological interventions, however 
further research needs to be done to determine the efficacy of each intervention 
alone, as well as combinations (Hetrick et al., 2010).  
According to the Department of Veterans Affairs/Department of Defense 
Clinical Practice Guidelines, first-line pharmacotherapy agents include SSRI and 
the SNRI venlafaxine.  Second-line agents include nefazodone, mirtazapine, 
TCAs, and MAOIs.  These agents are considered second line because they have 
less evidence for usefulness in treatment of PTSD, and have greater potential for 
side effects (Jeffreys et al., 2012). 
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Figure 4. Suggested lines of treatment in pharmacotherapy for PTSD.  Adapted 
from VA/DoD Clinical Practice Guideline for Management of Post-Traumatic 
Stress.(Jeffreys et al., 2012) 
 
The only two medications currently approved by the Food and Drug 
Administration for treatment of PTSD are the SSRIs sertraline and paroxetine.  
Both of these medications help to reduce the three core symptom clusters of 
PTSD: re-experiencing, hyperarousal, and avoidance.  These medications are 
hypothesized to be effective based on their affect on the serotonergic receptors, 
which as mentioned previously, have been shown to be altered in the amygdala 
of patients with PTSD.   Both drugs have been shown to be effective by 
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randomized controlled trials (Brady, 2000; Jeffreys et al., 2012; Marshall et al., 
2007). 
 
One of the most commonly prescribed SSRIs is sertraline (trade names Zolft, 
Lustral).  Bradey et al. (2000) conducted a large (n=187), multi-center, 
randomized placebo-controlled study to examine the efficacy of sertraline for the 
treatment of PTSD.  They found sertraline to be significantly more effective than 
placebo for the treatment of PTSD as measured by a number of assessments.  
Those taking sertraline had a 70% reduction in PTSD symptom severity in the 
first four weeks on the Clinician Administered PTSD Scale Part 2 (CAPS-2) and 
Impact of Event Scale (IES).  This is compared to the placebo response rate of 
32% (Brady, 2000).  They also found that 53% of subjects were either much or 
very much improved by the end of treatment (p=.008 vs placebo) (Brady, 2000). 
 
In a double-blind randomized controlled trial of paroxetine for chronic PTSD, 
subjects who received paroxetine were significantly more responsive than those 
on placebo, on a number of measures.  66.7% of those receiving paroxetine 
were classified as responders based on the Clinical Global Impression—
Improvement Scale (CGI-I), as compared to 27.3% of those treated with placebo.  
Subjects receiving paroxetine also showed greater reduction of dissociative 
symptoms and self-reported interpersonal problems.  Those receiving paroxetine 
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continued to improve during a 12-week maintenance phase, while those 
receiving placebo did not (Marshall et al., 2007). 
 
Other SSRIs have shown varying effectiveness.  Fluoxetine (Prozac, 
Sarafem, Fontex) has been shown to be superior to placebo in terms of treating 
PTSD symptoms, as well as preventing relapse (Davidson et al., 2005; Jeffreys 
et al., 2012; Martenyi & Soldatenkova, 2006).   
Citalopram (Celexa, Cipramil) and fluvoxamine (Luvox) have been less 
studied for their effectiveness in the treatment of PTSD (Jeffreys et al., 2012). 
 
The SNRI venlafaxine (effexor) is considered an off-label use in the 
treatment of PTSD, as it is not FDA approved for the treatment of PTSD (Jeffreys 
et al., 2012).  A randomized controlled trial has shown strong evidence that 
venlafaxine is effective in the treatment of PTSD (Davidson, 2006; Jeffreys et al., 
2012). 
 
Second-line medications recommended by the VA/DoD CPG include tricyclic 
antidepressents (TCAs) and monoamine oxidase inhibitors (MAOIs).  These 
medications are effective, but have considerably more side effects than SSRIs 
and SNRIs.  There is a relatively small difference between the therapeutic and 
toxic dosages of these medications, so they carry a risk of overdose (Jeffreys et 
al., 2012).   
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Also included in the list of second-line agents is Mitrazapine (Remeron, 
Avanza, Zispin), which can be a useful alternative to those who suffer from 
sexual side effects of SSRIs.  It acts on the serotonin system, and at high doses 
demonstrates noradrenergic stimulation (Chung et al., 2004; Jeffreys et al., 
2012). 
 
Nefazodone (Serzone, Nefadar) is also recommended as a second-line 
medication, however it should be used with extreme caution.  Liver failure has 
been reported in about 1:300,000 cases, so it is important to closely monitor liver 
functions in conjunction with using this medication.  Nefazodone has been shown 
to ameliorate some of the hyperarousal symptoms of PTSD such as sleep 
disturbance and anxiety (Davis et al., 2004; Jeffreys et al., 2012). 
 
Benzodiazepines and antipsychotic drugs have been used in the past for 
the treatment of PTSD despite a lack of evidence for their efficacy.  The 
prescription of benzodiazepines for PTSD can actually be quite harmful as they 
mask the outward symptom of anxiety without addressing the underlying PTSD.  
This may lead clinicians to believe that the patient has improved, when they in 
fact still remain untreated for their PTSD.  Benzodiazepines also have a higher 
potential for abuse than other drugs, and are thus contraindicated for patients 
with addiction problems.  Benzodiazepines have also been shown to interfere 
with fear extinction which is an integral part of prolonged exposure therapy 
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(Jeffreys et al., 2012).  Like benzodiazepines, antipsychotics have not been 
shown to be effective for PTSD treatment.  A large multisite VA cooperative study 
showed that the antipsychotic risperidone (Risperdal) was no more effective 
than placebo at decreasing PTSD symptoms over 24 weeks (Krystal, 2011, 
2011).  Antipsychotics also carry a risk of harmful side effects such as obesity 
and metabolic syndrome (Jeffreys et al., 2012). 
In addition to the established first- and second-line pharmaceutical 
treatments, there are also several emerging pharmaceuticals that are not yet 
approved for PTSD treatment. 
 
D-cycloserine (also known as DCS, Seromycin) holds the most significant 
potential as an emerging pharmacological treatment for PTSD (Cukor et al., 
2009).  D-cycloserine is a broad spectrum antibiotic, which has been used as a 
cognitive enhancer over last decade. It acts as a partial agonist at the N-methyl-
D-aspartate (NMDA) receptor, which plays an essential role in learning and 
memory.  D-cycloserine has also had positive results in the treatment of 
acrophobia, social phobia, and social anxiety.  It is hypothesized that D-
cycloserine may facilitate fear extinction, enhancing or accelerating treatment 
effects of Prolonged Exposure or Virtual Reality (Cukor et al., 2009).  
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Propanolol is a non-selective beta-adrenergic blocker used for hypertension.  
The theory behind its use in PTSD is that there is excessive epinephrine 
released during trauma, and that administration of propanolol immediately after 
may prevent development of PTSD (Cukor et al., 2009; Vaiva, 2003). 
 
Ketamine is a non-barbituate anesthetic, which acts as an antagonist at the 
NMDA receptor, and may cause disruption of memory process.  It is associated 
with dissociation and psychosis, which raises the concern that it may worsen 
PTSD (Cukor et al., 2009).  Surprisingly a retrospective chart review of OEF/OIF 
veterans showed that those who received ketamine had lower rates of PTSD 
than those who did not (McGhee et al., 2008). 
 
Prazosin is an alpha-1 adrenergic receptor blocker, used for hypertension 
and benign prostatic hyperplasia (Cukor et al., 2009). It has proved to be 
effective in treating PTSD-related nightmares (Calohan et al., 2010; Jeffreys et 
al., 2012; Taylor et al., 2008). 
 
MDMA (Methylenedioxymethamphetamine, Ecstasy) is a drug that results in 
positive moods, improved trust and emotional alliance.  It may contribute to 
successful treatment by helping to strengthen the therapeutic alliance.  However, 
negative emotions and psychobiological distress in aftermath seem to 
contraindicate its use in vulnerable populations (Cukor et al., 2009) 
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Clonidine is an alpha-2 adrenergic receptor agonist used to treat conditions 
such as hypertension, ADHD and a number of other conditions (“Clonidine: 
MedlinePlus Drug Information,” n.d.).  By blocking reconsolidation of persistent 
traumatic memories it may be effective in the treatment of PTSD.  In animal 
models it has been shown to disrupt fear-related memories in a dose-dependent 
manner, with lasting effects (Gamache, Pitman, & Nader, 2012). 
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Brain Stimulation Interventions 
 Individuals suffering from chronic PTSD often are not cured by 
psychotherapy and/or pharmacotherapy.  Brain stimulation offers an option which 
can be used as either an alternative to, or in conjunction with other treatment 
modalities.  Brain stimulation has been a useful treatment in psychiatry for 
several decades, but has not been extensively studied for the treatment of PTSD.  
It is hypothesized that the efficacy of other treatments may be in part due to relief 
of associated depression and anxiety.  Brain stimulation may be able to address 
PTSD in a more targeted way than other methods. The table below shows brain 
stimulation interventions and the conditions they are FDA approved to treat, and 
illustrates the differences between convulsive and non-convulsive; electrical and 
magnetic; and internal and external modalities (Novakovic et al., 2011). 
 
Vagus nerve stimulation (VNS) involves electrical pulses to activate vagal 
afferents.  It is invasive, as it requires surgical implantation of a device, but 
following the implantation the stimulation may continue wherever patients travel.  
VNS is FDA approved for the treatment of epilepsy and treatment resistant 
depression (TRD) (Novakovic et al., 2011).  VNS is hypothesized to be a 
potential treatment for anxiety disorders because the vagus nerve is involved in 
sending information to regions of the brain that are important for anxiety 
regulation.  When used for epilepsy and TRD patients have reported anxiolytic 
effects, confirming this hypothesis.  An open-label trial of VNS was well-tolerated 
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in subjects with a number of treatment-resistant anxiety disorders including panic 
disorder, obsessive compulsive disorder (OCD) and PTSD.   There was some 
efficacy in reducing anxiety, but this was primarily observed in the subjects with 
OCD.  There were only 2 subjects with PTSD, one of whom improved their 
anxiety ratings 41%, while the other had a worsened score by 3%.  It is difficult to 
draw conclusions about the effects on PTSD from this limited data, and future 
study may be limited due to the invasiveness of this procedure (George et al., 
2008). 
 
Transcranial Magnetic Stimulation (TMS) is a way of inducing cortical 
neurons to fire.  Repetitive TMS (rTMS) was approved by the FDA for treatment 
of major depression as well as migraine prophylaxis in 2008 (Novakovic et al., 
2011). Prefrontal rTMS has been shown to increase cerebral oxygen perfusion at 
high-frequency (20 Hz) and decrease cerebral oxygen perfusion at low-frequency 
(1 Hz) (Speer et al., 2000).  A placebo controlled trial of high-frequency (10 Hz) 
rTMS showed positive effects for treatment of PTSD (Cohen et al., 2004).  
Unfortunately these results have not yet been proven repeatable.  A more recent 
trial of rTMS combined with exposure therapy was also largely negative in 
results, although there was some reduction in hyperarousal.  This study was 
limited by sample size (n=9) and suggested that further exploration of optimal 
rTMS parameters is warranted.  (Osuch et al., 2009). 
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Electroconvulsive Therapy (ECT) is the oldest form of brain stimulation.  It 
was first introduced in 1938 and is regarded as a highly effective treatment for 
severe depression, mania and catatonia.  Electricity is applied to the scalp under 
general anesthesia to induce a seizure.  While the mechanisms are not 
completely understood, it is known that seizure induction is necessary for 
therapeutic effect.  It may be administered unilaterally or bilaterally, and other 
forms are being investigated.  While ECT has not been intensively studied for 
PTSD, it may have some efficacy for reducing comorbid depression (Novakovic 
et al., 2011).  Two case studies of women with co-morbid depression and PTSD 
have had positive results (Novakovic et al., 2011).  Margoob (2010) performed a 
prospective study of patients with severe, chronic, treatment-resistant PTSD.  
They received six bilateral ECT treatments and had a response rate of 82%, with 
a mean CAPS improvement of 40%.  These treatment gains were maintained at 
4-6 month follow-up (Novakovic et al., 2011). 
 
Cranial electrotherapy Stimulation (CES) is unique in that it can be self-
administered, unlike all other brain stimulation modalities.  It uses a small 
alternating current to affect brain function.  CES has been FDA approved for the 
treatment of depression, anxiety and insomnia since 1978.  It has yet to be 
studied for the treatment of PTSD, however it has been shown to reduce anxiety, 
which is promising (Novakovic et al., 2011). 
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Magnetic Seizure Therapy (MST) produces more focal seizures than ECT 
by applying high-intensity TMS under anesthesia.  There is no FDA approved 
indication for MST at this point, and much more research needs to be done 
before it can be used as a treatment for PTSD (Novakovic et al., 2011). 
 
Deep Brain Stimulation (DBS) is the most invasive and the most focal of the 
brain stimulation modalities.  It requires an electrode be surgically implanted to 
administer electrical stimulation.  DBS is FDA approved for a number of 
neurological conditions such as Parkinson’s and Epilepsy.  It is also approved for 
treatment resistant depression (TRD).  It has not yet been studied for PTSD, as 
specific targets in the must be identified first (Novakovic et al., 2011). 
Transcranial Direct Current Stimulation (tDCS) involves the polarization of 
brain tissue application of weak direct electrical currents to the scalp via sponge 
electrodes.  This results in changes of the excitability of the cortex that continue 
after the period of stimulation, in a similar manner to rTMS.  There is currently no 
FDA approved indication for the use of tDCS (Novakovic et al., 2011). 
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Comorbidities 
PTSD has an extremely high rate of occurrence with other comorbid 
conditions.  Studies have shown rates varying between 62% and 92% of subjects 
with PTSD having comorbidities (Kessler, 1995).  Whether PTSD is the cause or 
the effect of this high rate of comorbidities remains to be seen.   The national 
comorbidity study showed that PTSD was primary more often than not with 
comorbid affective disorders and substance use disorders.  However, PTSD was 
less likely to be the primary disorder with respect to anxiety disorders.  (Kessler, 
1995)   In studies of PTSD, comorbidities may frequently be cause to exclude 
patients from the trial in order to narrow the focus of the study to PTSD alone.  
This exclusion, however changes the sample to be one that is not at all 
representative of the general population.  When subjects are not excluded for 
comorbidities, the percentage of comorbidities is very high.  For example, in 
Osuch’s 2009 study of rTMS for PTSD, all subjects met criteria for current major 
depression and all subjects had a history of prior substance abuse (Osuch et al., 
2009). 
 
Traumatic Brain Injury (TBI) is defined by the Department of Defense 
and Department of Veterans Affairs (2009) as “a traumatically induced structural 
injury and/or physiological disruption of brain function as a result of an external 
force that is indicated by new onset or worsening of at least one of the following 
clinical signs, immediately following the event: any period of loss of or a 
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decreased level of consciousness (LOC), any loss of memory for events 
immediately before or after the injury (post-traumatic amnesia [PTA]), any 
alteration in mental state at the time of the injury (confusion, disorientation, 
slowed thinking, etc.) (alteration of consciousness/mental state [AOC]), 
neurological deficits (weakness, loss of balance, change in vision, praxis, 
paresis/plegia, sensory loss, aphasia, etc.) that may or may not be transient, and 
intracranial lesion. (p. 7) (“VA/DoD Clinical Practice Guidelines,” 2009). 
TBI may be categorized as mild, moderate or severe.  When symptoms 
persist for an extended period of time, they are termed Postconcussive 
symptoms or syndrome (PPCS).  These symptoms can be divided into three 
categories: somatic, psychological and cognitive (Wall, 2012). 
It can be difficult to differentiate symptoms of PTSD from those of a mild TBI.  
Sleep disturbances, increased arousal, irritability and decreased concentration 
are common features of both conditions (Jeffreys et al., 2012). 
 
Substance abuse is one of the most common comorbidities seen in 
individuals suffering from PTSD.  According to a national epidemiological survey, 
more than 40% of women in the U.S. diagnosed with PTSD also met criteria for 
an alcohol use disorder (Pietrzak et al., 2011). Additionally, in a survey of 
OEF/OIF/OND infantry teams, 25%  reported alcohol misuse post-deployment.  
The greatest predictor of alcohol-related problems upon returning home was the 
experience of direct threat of death and injury while deployed (Wilk et al., 2010).  
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Furthermore, it was shown that service members who experienced multiple 
deployments had increased alcohol-related issues than those who had only 
deployed once (Carter et al., 2011). 
There are multiple theories as to why there is such a high rate of comorbid 
PTSD and substance abuse.  One pervasive theory is that substances are used 
as self-medication.  Many individuals are believed to be using alcohol to alleviate 
symptoms & reduce negative emotions (Carter et al., 2011; Waldrop et al., 2007). 
A second theory for the high rate of comorbid PTSD and substance abuse 
is that there is a common factor underlying both problems.  Individuals may 
possess a lack of awareness and understanding of their emotions, as well as an 
inability to control behaviors when in emotional distress (Bornovalova et al., 
2009; Brady, 2000; Carter et al., 2011). 
Surveys have shown that professionals find comorbid PTSD and 
substance use disorder more difficult to treat than PTSD alone (Najavits, 2012).  
In addition, it has been shown that a diagnosis of co-occurring alcohol use 
disorder with PTSD is more detrimental than diagnosis of either alcohol use 
disorder or PTSD alone (Carter et al., 2011). 
The traditional treatment for comorbid PTSD and alcohol use disorders is to 
treat each condition separately in a sequential manner.  This approach has 
proven problematic because of high dropout and relapse rates (Carter et al., 
2011)  Another approach, termed parallel treatment, is to treat the two disorders 
simultaneously but separately.  This is preferable to sequential treatment, 
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however can be uneven and confusing for patients as treatment may not be 
consistent across separate providers and clinics (Carter et al., 2011; Karlin et al., 
2010).  Ideally, treatment of PTSD and alcohol use disorder would be integrated.   
While trauma focused therapies have been shown to be the most successful 
for treating PTSD alone, clinicians are reluctant to implement these therapies in 
those with comorbid substance abuse for fear that it may be unsafe.  They fear 
that triggering a negative affect may cause patients to engage in riskier 
behaviors, as supported by the self-medication hypothesis.   
“Until recently… many experts and clinicians considered the use of prolonged 
exposure therapy among individuals with substance dependence to be 
inappropriate unless a lengthy period of abstinence had been achieved.  Based 
on early case reports, it was widely believed that intense emotions elicited during 
prolonged exposure could place individuals at increased risk for relapse.  There 
is however, an absence of evidence to support or refute this recommendation, 
because most trials of PTSD treatment have excluded individuals with substance 
dependence.”  (Bradley et al., 2005; Mills, 2012). 
In order to combine treatment, coping skills could be taught alongside 
standard PTSD interventions, such as prolonged exposure.  One such study has 
shown reductions in both PTSD and alcohol use disorder symptoms.  (Coffey et 
al., 2006).  Unfortunately these integrated treatments show high attrition rates, so 
therapies that are not exposure-based should also be explored (Coffey et al., 
2010).  Najavits (2002) explored a coping-skills based group therapy for co-
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occurring PTSD and substance abuse, entitled “Seeking Safety”.  Though this 
trial demonstrated some efficacy, others have had mixed results, and a pilot of 
Seeking Safety with veterans had significant engagement and retention 
difficulties (Carter et al., 2011; Norman et al., 2010). 
One treatment being studied for the treatment of comorbid PTSD and 
substance is termed “Concurrent Treatment of PTSD and Substance Use 
Disorders Using Prolonged Exposure (COPE)” (Back et al., 2012; Mills, 2012). 
Back’s 2012 case study shows an ideal example of COPE.  It explains 
how an individual progressed through therapy and had significant improvements 
(Back et al., 2012). 
Mills’ 2012 RCT of COPE showed that subjects improved PTSD 
symptoms, but there was no significant difference with or without substance 
abuse (Table 2).  This is the first RCT to assess efficacy of PE for PTSD in 
subjects with co-occurring substance dependence.  Najavits (2012) praises this 
trial for the “inclusion of well-trained clinicians, monitoring of treatments quality, 
measurement of amount of therapies provided as usual treatment, validated 
measures of patient outcomes, and appropriate statistical analyses.”  They also 
lauded the broad range of subjects included, which are usually excluded from 
other studies.  The subjects in the Mills experiment were not paid, which 
strengthens the data further, as payment may artificially inflate results.  (Najavits, 
2012)
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Major depressive disorder (MDD) has a number of overlapping symptoms 
with PTSD, such as irritability, social withdrawal and sleep disturbance.  For this 
reason it is not uncommon for patients to meet the diagnostic criteria for both 
PTSD and MDD (Jeffreys et al., 2012). 
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SUGGESTIONS FOR FUTURE RESEARCH 
While research surrounding PTSD treatments is on the rise, and has 
become a point of focus in the news as of late, there still exists many questions 
to be answered, research to be done and problems to address. 
One major issue, which is difficult to address, is that experimental data 
contains gaps due to exclusion and inclusion criteria.  Some of the most typical 
PTSD patients have comorbidities or other conditions which exclude them from 
PTSD research.  Najavits (2012) observes that many groups have been 
consistently excluded in clinical trials of PTSD treatments to date.  Clinicians 
routinely encounter complex cases of PTSD,  and a typical individual suffering 
from PTSD may be excluded from a clinical trial for reasons including comorbid 
conditions such as substance use disorder; suicidal ideation; histories of self-
harm, homelessness, and intimate partner violence (Najavits, 2012). 
Even when individuals suffering from PTSD are not involuntarily excluded 
from research, the disorder itself may prevent them from participation.  
Estrangement from others and decreased participation in activities are common 
symptoms, and when coupled with a sense of hopelessness, a patient may be 
less than willing to participate in any medical care, much less research (Jeffreys 
et al., 2012). 
When subjects with PTSD overcome the above barriers and are 
successfully enrolled in clinical trials, it is not uncommon for subjects to drop out 
of research studies, which may skew results. Variables that might affect 
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treatment completion is an important topic for future research (Resick et al., 
2002).   
CPT has been shown efficacious as a treatment for PTSD, but studies so 
far have only been done with rape victims.  It is necessary to test with other 
populations in order to ensure generalizability.  Effectiveness studies are also 
needed in for generalization to non-research settings (Resick et al., 2002). 
While there is a significant amount of research on comorbid conditions 
such as TBI and substance abuse, there is very little for Axis II disorders and 
bipolar disorder.  These disorders are difficult to treat alone, and become more 
complicated with combined with PTSD.  There have been some studies on the 
use of mood stabilizers and antipsychotics for comorbid bipolar disorder with 
PTSD, but these have had little success (Jeffreys et al., 2012).  Further research 
needs to be done on the best course of treatment in cases such as these. 
In addition to the areas described above where research could be improved, 
another important issue to address is the gap between research and practice.  
Even when a treatment is deemed successful by researchers, and the evidence 
and recommendations are disseminated to providers, the treatments may, and 
often are not, implemented (Karlin et al., 2010).   
Even when clinicians do have the desire and resources to apply research to 
practice it can be confusing to figure out what the best course of treatment is.  
Several clinical practice guidelines exist; to the extent that Forbes et al. (2010) 
wrote a “Guide to Guidelines” in order to assist clinicians in sorting out these 
 40 
recommendations and making decisions about their use.  This review explained 
that, “clinical practice guidelines are systematically developed statements to 
assist practitioner and patient decisions about appropriate health care for specific 
clinical circumstances.”  They performed a systematic review of seven of these 
guidelines for the treatment of PTSD-- VA/DoD, APA, NICE, NHMRC, ISTSS, 
AACAP and IOM.  (Forbes et al., 2010)  The guidelines review showed many 
areas of concurrence in their recommendations for treatment of PTSD.  The use 
of trauma-focused psychological treatment was strongly supported by all 
guidelines.  All guidelines also acknowledged some benefit of pharmacotherapy.  
SSRIs were the most commonly recommended pharmacotherapy, though the 
degree to which they were recommended varied.  Some guidelines 
recommended that SSRIs only be used as a second line intervention.  EMDR 
was mentioned in all guidelines, however there was disagreement as to whether 
it was acceptable as a first line treatment. 
When evidence-based treatments are successfully implemented in 
practice, obstacles and barriers to care still remain.  There are unique problems 
to both veterans and active duty when it comes to having access to the treatment 
they need for PTSD.  One case study describes veteran did not seek treatment 
for many years because a bad experience with the VA in the 70’s caused him to 
distrust the “system” (Back et al., 2012).  One major factor is underreporting, 
which in itself has a variety of causes.  Among active duty personnel there is a 
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stigma associated with mental health disorders and fear of negative effect on 
one’s career.  (Hoge et al., 2004; Iversen et al., 2011; Wall, 2012). 
Additional problems include lack of anonymity and lack of time off for 
active duty personnel (Iversen et al., 2011).  These barriers to care are not 
exclusive to PTSD, but apply to other mental health problems as well.  Despite a 
high prevalence of alcohol misuse in military populations, the rates of those 
seeking help for alcohol problems are particularly low (Iversen et al., 2011).  In 
addition, personnel with anxiety or  depression are twice as likely as those who 
are well to report stigmatizing beliefs about mental health problems (Hoge et al., 
2004; Iversen et al., 2011). 
In an anonymous screen of personnel returning to the U.S. from Iraq and 
Afghanistan, 15.7% met broad criteria for PTSD.  This rate is statistically 
significant from the 7.8% who met broad criteria in a retrospective review of the 
mandated non-anonymous screen.  This result may indicate underreporting of 
PTSD, however it should not be overlooked that the anonymous screen was 
voluntary, whereas the on-the-record screenings are mandated for service 
members returning from deployment (McLay, 2008). 
As different types of therapy are explored, clients should be matched with 
specific therapies based on their individual symptomology.  As certain treatments 
have shown to be more effective at ameliorating specific symptoms, there may 
be variation in which treatment is effective for an individual patient. 
 42 
Translation from research to practice should be another area of focus for mental 
health professionals.   Despite the strong evidence and practice guidelines that 
support the use of CBT for PTSD, many mental health clinics are still using 
psychodynamic-oriented, supportive therapy as a common treatment for PTSD 
(Nacasch et al., 2011). 
Literature on this topic is very recent, as the term PTSD was only coined 
in the 1970’s, when the disorder started to become more widely recognized 
following the war in Vietnam.  Of course, the disorder existed previously, but 
research has only taken off recently.  The disorder was added to the third edition 
of the Diagnostic and Statistical Manual of Mental Disorders in 1980. 
One important point to consider is that different treatments may work 
differently on specific trauma populations.  Veterans have a very different 
experience than other trauma survivors.  While many sufferers from PTSD often 
have reactions of guilt and shame, these feelings often have rational foundations 
in veterans.  A survivor of rape or assault may blame themselves for allowing the 
incident to have happened, which most would view as an irrational thought.  A 
veteran who killed innocent civilians has more of a rational basis for his guilt, and 
thus may resist the attempts to challenge these feelings.  Instead of trying to 
decondition this thought process, it may be more constructive  to explore was of 
bearing witness and making reparations through vehicles such as volunteer work 
(E. B. Foa & Meadows, 1997a). 
 43 
Each group of PTSD patients has a unique set of factors to consider.  
Victims of sexual assault, for example, must face the fear that their trauma may 
reoccur without warning.  This is not something that veterans have to face, as 
they have been removed from the setting of their trauma.  Victims of childhood 
abuse also have unique circumstances, as their trauma may have altered their 
development.  Oftentimes, victims of childhood abuse must reconstruct what they 
view as normal, which is a unique challenge in treatment (Foa & Meadows, 
1997a). 
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